Clarity Pharmaceuticals (ASX:CU6) completed the dose escalation phase of its SECuRE trial, according to a Wednesday Australian bourse filing.
The safety review committee recommended that it proceed to the cohort expansion phase of the study at eight gigabecquerel dose level and increase the number of cycles from four to up to six.
The SECuRE trial assesses the safety and efficacy of the drug in the treatment of patients with metastatic castrate-resistant prostate cancer.
It said that across all cohorts of the dose escalation phase, 68% of the participants showed a reduction in prostate-specific antigen, despite 77% of the participants only receiving a single dose of copper-67-SAR-bisPSMA. It also showed a favorable safety profile across all cohorts.
The SECuRE trial protocol was amended to administer copper-67-SAR-bisPSMA to participants at earlier stages of the disease, in a pre-chemotherapy setting, incorporating an increase in the number of participants from 14 to 24, with a subset expected to receive a combination with enzalutamide.
The firm's shares rose 4% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。